Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Treatment of BRAF(V600E) mutant melanoma by small molecule drugs that target the BRAF or MEK kinases can be effective, but resistance develops invariably. In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). Here we show that 6 out of 16 melanoma tumours analysed acquired EGFR expression after the development of resistance to BRAF or MEK inhibitors. Using a chromatin-regulator-focused short hairpin RNA (shRNA) library, we find that suppression of sex determining region Y-box 10 (SOX10) in melanoma causes activation of TGF-β signalling, thus leading to upregulation of EGFR and platelet-derived growth factor receptor-β (PDGFRB), which confer resistance to BRAF and MEK inhibitors. Expression of EGFR in melanoma or treatment with TGF-β results in a slow-growth phenotype with cells displaying hallmarks of oncogene-induced senescence. However, EGFR expression or exposure to TGF-β becomes beneficial for proliferation in the presence of BRAF or MEK inhibitors. In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples. Our findings provide a rationale for why some BRAF or MEK inhibitor-resistant melanoma patients may regain sensitivity to these drugs after a 'drug holiday' and identify patients with EGFR-positive melanoma as a group that may benefit from re-treatment after a drug holiday.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, adaptive feedback resistance has been a key limitation in prior clinical efforts to target the RAS-MAPK pathway.”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, RTK-driven feedback reactivation of RAS-MAPK signaling has been identified as a key driver of resistance in BRAFV600E cancers treated with BRAF inhibitors (colorectal cancer in particular) and in KRAS-mutant cancers treated with MEK inhibitors (11,12,32).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated that in BRAF V600E mutant cancers, BRAF inhibition can lead to rapid EGFR-mediated feedback activation [95,96,104].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [104]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Self-citationBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationCOT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., et al. (2010) · Nature · doi:10.1038/nature09627 · Cited by 1,460
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Cited by
Items 201–300 of 916
Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy
Huang, F., Santinon, F., González, R. E. F., & Rincon, S. V. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756001 · Cited by 75
“receptors, allowing them to grow, bypassing the MAPK signaling and thereby permitting MAPKi resistance (10, 14, 16, 39, 54, 71, 75, 76, 78, 80, 189, 190).”
BackgroundInfluentialTGF-β Modulated Pathways in Colorectal Cancer: New Potential Therapeutic Opportunities
Fasano, M., Pirozzi, M., Miceli, C. C., Cocule, M., Caraglia, M., Boccellino, M., Vitale, P., Falco, V. D., Farese, S., Zotta, A., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137400 · Cited by 69
“BRAFi-treated melanoma cells show increased EGFR, PDGFRB, and miR-125a expression due to TGF-β signaling, reducing pro-apoptotic pathway activity and fostering BRAFi resistance [141,142].”
BackgroundBase editing screens define the genetic landscape of cancer drug resistance mechanisms
Coelho, M. A., Strauß, M. E., Watterson, A., Cooper, S., Bhosle, S. G., Illuzzi, G., Karakoç, E., Dinçer, C., Vieira, S. F., Sharma, M., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01948-8 · Cited by 75
“Drug holidays have been proposed to mitigate the emergence of these drug-resistant cancer cell clones 42–44 .”
Diener, J., & Sommer, L. (2021) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0351 · Cited by 64
Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells
Misek, S. A., Appleton, K. M., Dexheimer, T. S., Lisabeth, E. M., Lo, R. S., Larsen, S. D., Gallo, K. A., & Neubig, R. R. (2019) · Oncogene · doi:10.1038/s41388-019-1074-1 · Cited by 73
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma
Rosenberg, T., Yeo, K. K., Mauguen, A., Alexandrescu, S., Prabhu, S. P., Tsai, J. W., Malinowski, S. W., Joshirao, M., Parikh, K. M., Sait, S. F., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac096 · Cited by 64
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Timofeev, O. N., Giron, P., Lawo, S., Pichler, M., & Noeparast, A. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00554-5 · Cited by 75
“The slowdown in proliferation was associated with cellular senescence as suggested by hypophosphorylation of RB1 and induction of CDKN1A, CDKN1B, and Beta-galactosidase 203 .”
BackgroundRedmer, T., Walz, I., Klinger, B., Khouja, S., Welte, Y., Schäfer, R., & Regenbrecht, C. R. A. (2017) · Oncogenesis · doi:10.1038/oncsis.2016.88 · Cited by 69
METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation
Bhattarai, P. Y., Kim, G., Poudel, M., Lim, S., & Choi, H. S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.09.015 · Cited by 65
Nanoparticle-Mediated Drug Delivery for Treating Melanoma
Mundra, V., Li, W., & Mahato, R. I. (2015) · Nanomedicine · doi:10.2217/nnm.15.111 · Cited by 68
Diazzi, S., Tartare‐Deckert, S., & Deckert, M. (2023) · Oncogenesis · doi:10.1038/s41389-023-00452-8 · Cited by 72
ERK Inhibition: A New Front in the War against MAPK Pathway–Driven Cancers?
Smalley, I., & Smalley, K. S. M. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1355 · Cited by 58
Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research.
Bhatia, P., Friedlander, P. L., Elmageed, Z. A., & Kandil, E. H. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2014.12.05 · Cited by 60
“Recently, Sun and colleagues have examined the idea of reversing acquired BRAF-resistance in melanoma (34).”
BackgroundVià, M. D., Solimando, A. G., Garitano-Trojaola, A., Barrio, S., Munawar, U., Strifler, S., Haertle, L., Rhodes, N., Teufel, E., Vogt, C., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0356 · Cited by 62
Nulali, J., Zhang, K., Long, M., Wan, Y., Liu, Y., Zhang, Q., Yang, L., Hao, J., Yang, L., & Song, H. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.82316 · Cited by 61
“EGFR is a transmembrane receptor tyrosine kinase protein that belongs to the ErbB family and is considered dysregulated in many different types of tumors [18-21].”
BackgroundDisrupting cellular memory to overcome drug resistance
Harmange, G., Hueros, R. A. R., Schaff, D. L., Emert, B., Saint-Antoine, M., Kim, L. C., Niu, Z., Nellore, S., Fane, M. E., Alicea, G. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41811-8 · Cited by 60
“The dedifferentiated state is similar to our primed cell population as these cells are also characterized by their decreased expression of melanocyte transcription factors SOX10 and MITF (Tirosh et al. 2016; Sun et al. 2014; Lee et al. 2020; Hoek et al. 2008).”
BackgroundResultAdaptive resistance to RAF inhibitors in melanoma
Kugel, C. H., & Aplin, A. E. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12264 · Cited by 64
de la Rochefordière, A., Kamal, M. T., Floquet, A., Thomas, L., Petrow, P. K., Petit, T., Pop, M., Fabbro, M., Kerr, C., Joly, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2368 · Cited by 61
Precision medicine, genomics and drug discovery: Table 1.
Cardon, L. R., & Harris, T. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw246 · Cited by 65
Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies
Saei, A., Palafox, M., Benoukraf, T., Kumari, N., Jaynes, P. W., Iyengar, P. V., Muñoz‐Couselo, E., Nuciforo, P. G., Cortés, J., Nötzel, C., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171960 · Cited by 58
“These include up-regulation of receptor tyrosine kinases or growth factors (EGFR and ERBB3), activating mutations in MEK or NRAS, loss of expression of the NRAS negative regulator NF1, or the expression of alternatively spliced variants of BRAF (Nazarian et al., 2010; Poulikakos et al., 2011; Shi et al., 2012; Wilson…”
BackgroundPersonal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
Cheng, F., Liang, H., Butte, A. J., Eng, C., & Nussinov, R. (2018) · Pharmacological Reviews · doi:10.1124/pr.118.016253 · Cited by 61
“…such as epidermal growth factor receptor (EGFR)-T790M in non-small cell lung cancer (NSCLC) (Pao and Hutchinson, 2012), BRAF-V600E in melanoma (Sun et al., 2014), HER2 amplification in breast cancer (Arteaga and Engelman, 2014), BCR-ABL fusion oncoprotein in chronic myeloid leukemia (CML),…”
BackgroundAdaptive Resistance to an Inhibitor of Chromosomal Instability in Human Cancer Cells
Orr, B., Talje, L., Liu, Z., Kwok, B. H. B., & Compton, D. A. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.030 · Cited by 60
“…based on molecular profiling in tumor cells (Barretina et al., 2012; Garnett et al., 2012) has been limited by rapid alterations of cellular signaling and/or transcriptional networks responsible for generating adaptive resistance (Litvin et al., 2015; Muranen et al., 2012; Sun et al., 2014).”
BackgroundWang, V. E., Xue, J. Y., Frederick, D. T., Cao, Y., Lin, E., Wilson, C., Urisman, A., Carbone, D. P., Flaherty, K. T., Bernards, R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2779 · Cited by 54
“Tumors in the dual combination arm grew after approximately 14 days, although interestingly, tumors in the vehicle and single-agent ponatinib-treated animals remained static, which may be related to oncogene-induced senescence upon withdrawal of the inhibitors as reported previously (28).”
BackgroundMethodSelf-citationHartman, M. L., Sztiller-Sikorska, M., Gajos-Michniewicz, A., & Czyż, M. (2020) · Cells · doi:10.3390/cells9010142 · Cited by 57
“Furthermore, downregulation of SOX10 removal of the drug from the culture medium resulted in EGF-independent proliferation of both cell lines, which was especially surprising for 28_TRAR cells (Figure 4E).”
InfluentialROCK 1 is a potential combinatorial drug target for BRAF mutant melanoma
Smit, M. A., Maddalo, G., Greig, K., Raaijmakers, L. M., Possik, P. A., van Breukelen, B., Cappadona, S., Heck, A. J., Altelaar, A. M., & Peeper, D. S. (2014) · Molecular Systems Biology · doi:10.15252/msb.20145450 · Cited by 54
Cao, Y., Liang, H., Zhang, F., Luan, Z., Zhao, S., Wang, X.-A., Liu, S., Bao, R., Shu, Y., Ma, Q., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0346-7 · Cited by 58
“Unfortunately, cancer cells quickly adapt to these new targeted agents, and tumors with acquired resistance can emerge within several months following the primary treatments [9–11].”
BackgroundMassi, D., Mihic‐Probst, D., Schadendorf, D., Dummer, R., & Mandalà, M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102060 · Cited by 61
BRAF Mutation in Colorectal Cancers: From Prognostic Marker to Targetable Mutation
Nakayama, I., Hirota, T., & Shinozaki, E. (2020) · Cancers · doi:10.3390/cancers12113236 · Cited by 65
Keller, H. R., Zhang, X., Li, L., Schaider, H., & Wells, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.18523 · Cited by 58
Jiang, P., Lee, W., Li, X., Johnson, C., Liu, J. S., Brown, M. A., Aster, J. C., & Liu, X. S. (2018) · Cell Systems · doi:10.1016/j.cels.2018.01.009 · Cited by 62
“This observation is consistent with the knowledge that EGFR activation promotes resistance to BRAF inhibitors (Sun et al., 2014).”
Smalley, I., Law, V., Wyatt, C. J., Evernden, B. R., Fang, B., Koomen, J. M., Welsh, E. A., Macaulay, R. J. B., Forsyth, P. A., & Smalley, K. S. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2840 · Cited by 58
“This switch to a TGFb expression signature is frequently associatedwith increased expression of multiple RTKs including EGFR and PDGR leading to therapeutic escape (23, 47).”
InfluentialZuo, Z., Liu, X., Qian, X., Zeng, T., Sang, N., Liu, H., Zhou, Y., Tao, L., Zhou, X., Su, N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00512 · Cited by 61
Overcoming resistance to targeted therapies in chronic lymphocytic leukemia
Skånland, S. S., & Mato, A. R. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003423 · Cited by 56
“Two clinical studies suggest that treatment resistance can be reversed by a drug holiday in BRAF(V600E) mutant melanoma patients who progress on BRAF inhibitors.(55,56) Importantly, resistance to BRAF inhibitors is not associated with acquired mutations in the drug target.”
BackgroundFunction-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor
Kugel, C. H., Hartsough, E. J., Davies, M. A., Setiady, Y. Y., & Aplin, A. E. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0464 · Cited by 54
“Recently, EGFR has been implicated in intrinsic resistance to BRAF inhibitor (29, 30).”
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency
Ceccon, M., Merlo, M. E. B., Mologni, L., Poggio, T., Varesio, L. M., Menotti, M., Bombelli, S., Rigolio, R., Manazza, A. D., Giacomo, F. D., et al. (2015) · Oncogene · doi:10.1038/onc.2015.456 · Cited by 54
MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
Kim, E. J., Zucconi, B. E., Wu, M., Nocco, S. E., Meyers, D. J., McGee, J. S., Venkatesh, S., Cohen, D. L., Gonzalez, E. C., Ryu, B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2331 · Cited by 56
Taking advantage of drug resistance, a new approach in the war on cancer
Wang, L., & Bernards, R. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0647-7 · Cited by 53
Self-citationSinnberg, T. W., Makino, E., Krueger, M. A., Velić, A., Maček, B., Rothbauer, U., Groll, N., Poetz, O., Czemmel, S., Niessner, H., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.037 · Cited by 57
“inhibitors correlated with the activation of PI3K/AKT signaling pathway which is achieved by up-regulation of receptor tyrosine kinases (RTKs) such as platelet-derived growth factor receptor (PDGFR) beta, vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), insulin-growth facto…”
BackgroundBiomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
Eskiocak, B., McMillan, E. A., Mendiratta, S., Kollipara, R. K., Zhang, H., Humphries, C. G., Wang, C., García‐Rodríguez, J., Ding, M. L., Zaman, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0955 · Cited by 57
“SOX10 Addiction Specifies Sensitivity of BRAF-Mutant Melanomas to BRAF and MEK Inhibitors In Vitro and in Patients SOX10 suppression has been reported to be associated with resistance to BRAF-targeted therapy in melanoma, at least in part as a consequence of increased TGFβ receptor 2 (TGFBR2) expression (12).”
BackgroundRao, L., Giannico, D., Leone, P., Solimando, A. G., Maiorano, E., Caporusso, C., Duda, L., Tamma, R., Mallamaci, R., Susca, N., et al. (2020) · Cancers · doi:10.3390/cancers12010173 · Cited by 57
Defining and Targeting BRAF Mutations in Solid Tumors
Halle, B. R., & Johnson, D. B. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00827-2 · Cited by 57
Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
Trojaniello, C., Luke, J. J., & Ascierto, P. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670726 · Cited by 58
“BRAF-resistant melanomas usually determine a reactivation of the MAPK signaling pathway (9).”
BackgroundSa, R., Liang, R., Qiu, X., He, Z., Liu, Z., & Chen, L. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.12.005 · Cited by 59
Fufa, T. D., Harris, M. L., Watkins-Chow, D. E., Levy, D., Gorkin, D. U., Gildea, D. E., Song, L., Safi, A., Crawford, G. E., Sviderskaya, E. V., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv267 · Cited by 49
Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance
Smith, M. P., & Wellbrock, C. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0954 · Cited by 51
“For instance, overexpression of EGFR/platelet-derived growth factor receptor (PDGFR) is an indirect consequence of MAPK pathway inhibition due to the enrichment of EGFR cells from a heterogeneous population determined by variable levels of its transcriptional repressor SOX10 (30).”
BackgroundAvram, Ș., Coricovac, D. E., Pavel, I. Z., Pînzaru, I., Ghiulai, R. M., Baderca, F., Şoica, C., Muntean, D. M., Branisteanu, D. E., Spandidos, D. A., et al. (2017) · Oncology Reports · doi:10.3892/or.2017.5658 · Cited by 52
“The recent advances in the molecular therapy of mutant melanoma are considerable; however, this type of therapy is still confronted with secondary effects and is resistant to treatment (7-9).”
BackgroundCOP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors
Xie, Y., Cao, Z., Wong, E. W. P., Guan, Y., Ma, W., Zhang, J. Q., Walczak, E. G., Murphy, D. A., Ran, L., Sirota, I., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci94840 · Cited by 69
Utility of the JAX Clinical Knowledgebase in capture and assessment of complex genomic cancer data
Patterson, S. E., Statz, C. M., Yin, T., & Mockus, S. M. (2019) · npj Precision Oncology · doi:10.1038/s41698-018-0073-y · Cited by 48
Jessen, C., Kreß, J. K. C., Baluapuri, A., Hufnagel, A., Schmitz, W., Kneitz, S., Roth, S., Marquardt, A., Appenzeller, S., Ade, C. P., et al. (2020) · Oncogene · doi:10.1038/s41388-020-01535-1 · Cited by 51
Opportunities and challenges provided by crosstalk between signalling pathways in cancer
Prahallad, A., & Bernards, R. (2015) · Oncogene · doi:10.1038/onc.2015.151 · Cited by 56
Self-citationCancer pharmacogenomics, challenges in implementation, and patient-focused perspectives
Patel, J. N. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s62918 · Cited by 55
“inhibitor with a MEK inhibitor has been a logical approach to combat BRAF inhibitor resistance.(32) In a Phase III trial, investigators randomly assigned 704 patients with BRAF V600E-positive metastatic melanoma to receive either a combination of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) or vemurafeni…”
Role Of YAP Signaling in Regulation of Programmed Cell Death and Drug Resistance in Cancer
Zhou, W., Lim, A., Edderkaoui, M., Osipov, A., Wu, H., Wang, Q., & Pandol, S. J. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83586 · Cited by 52
“Although BRAF inhibitors have shown benefit in melanoma patients with the oncogenic BRAF V600E mutant, acquired drug resistance remains a significant obstacle [90].”
BackgroundAchievements and Challenges of Molecular Targeted Therapy in Melanoma
Sullivan, R. J., LoRusso, P. M., Boerner, S. A., & Dummer, R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.177 · Cited by 52
Girotti, M. R., Saturno, G., Lorigan, P. C., & Marais, R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.027 · Cited by 59
Wang, C., Zhao, L., Su, Q., Fan, X., Wang, Y., Gao, S., Wang, H., Chen, H., Chan, C. B., & Liu, Z. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.09.029 · Cited by 52
Phenotypic heterogeneity and evolution of melanoma cells associated with targeted therapy resistance
Lü, Y., Bintz, M., Yang, Y., Robert, L., Ng, A. H. C., Liu, V., Ribas, A., Heath, J. R., & Wei, W. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007034 · Cited by 52
Wessely, A., Steeb, T., Berking, C., & Heppt, M. V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115761 · Cited by 55
Li, Z., Wang, Z., Tang, Y., Lu, X., Chen, J., Dong, Y., Wu, B., Wang, C., Liu, Y., Guo, Z., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11808-3 · Cited by 52
Chang, L., Jung, N. Y., Atari, A., Rodriguez, D. J., Kesar, D., Song, T., Rees, M. G., Ronan, M. M., Li, R., Ruiz, P. A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01515-7 · Cited by 61
The c-Jun/RHOB/AKT pathway confers resistance ofBRAF-mutant melanoma cells to MAPK inhibitors
Delmas, A., Cherier, J., Pohorecka, M., Giamarchi, C. M., Meyer, N., Casanova, A., Sordet, O., Lamant, L., Savina, A., Pradines, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3888 · Cited by 48
“Most of them reactivate the MAPK and/or PI3K/AKT pathways by acquisition of RAS and MEK mutations [7, 8], or over-expression of COT [9], CRAF or growth factor receptor such as FGFR3, EGFR, PDGFRα, PDGFRβ [7, 10–13].”
BackgroundKoetz‐Ploch, L., Hanniford, D., Dolgalev, I., Sokolova, E., Zhong, J., Díaz‐Martínez, M., Bernstein, E., Darvishian, F., Flaherty, K. T., Chapman, P. B., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12578 · Cited by 53
“Strikingly, the most highly correlated mRNA was TGFb1 (r2 = 0.8, P < 0.00001; Figure 4G), which has previously been implicated in acquisition of BRAFi resis- tance (Sun et al., 2014).”
InfluentialChiu, Y., Yang, J., Tsai, F., Chiu, H., Juan, Y., Lo, Y., & Chiang, J. (2022) · Environmental Toxicology · doi:10.1002/tox.23450 · Cited by 49
“signaling pathways (RAS/MEK/ERK and PI3K/AKT) contribute to EGFR signaling.(48) Su et al.”
BackgroundBMI1 induces an invasive signature in melanoma that promotes metastasis and chemoresistance
Ferretti, R., Bhutkar, A. J., McNamara, M. C., & Lees, J. A. (2015) · Genes & Development · doi:10.1101/gad.267757.115 · Cited by 52
“2014]) andWM164 (GSE54711) cells after culture in vehicle or BRAFi (left panel) or three paired biopsies from melanoma patients before and after treatment with vemurafenib (GSE50535 [Sun et al. 2014]) (right panel).”
Dugo, M., Nicolini, G., Tragni, G., Bersani, I., Tomassetti, A., Colonna, V., Vecchio, M. D., de Braud, F., Canevari, S., Anichini, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3007 · Cited by 49
“In one study, 6 posttreatment biopsies from 16 patients who developed resistance to BRAFi or MEKi expressed EGFR [28]; in another, EGFR was hyperphosphorylated in 4 post-therapy lesions from 5 relapsed patients [23].”
BackgroundInfluentialNew therapeutic options for advanced non-resectable malignant melanoma
Stadler, S., Weina, K., Gebhardt, C., & Utikal, J. S. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.12.002 · Cited by 55
“To date, many different resistance mechanisms have been described [21–23].”
BackgroundFriedman, A. A., Amzallag, A., Pruteanu-Malinici, I., Baniya, S., Cooper, Z. A., Piris, A., Hargreaves, L., Igras, V., Frederick, D. T., Lawrence, D. P., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140310 · Cited by 57
“While PDGFRα and β overexpression previously has been linked to acquired vemurafenib resistance [6, 7, 26], this family has not been implicated in cell-autonomous primary vemurafenib resistance.”
BackgroundPhenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma
Roesch, A., Paschen, A., Landsberg, J., Helfrich, I., Becker, J. C., & Schadendorf, D. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.023 · Cited by 53
“Also the incubation of melanoma cells with recombinant TGF-b was shown to induce BRAFinhibitor resistance via upregulation of EGFR and PDGFRb [24].”
BackgroundTargeting the lncRNA SAMMSON Reveals Metabolic Vulnerability in Melanoma
Goding, C. R. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.010 · Cited by 47
“However, because SOX10 also regulates MITF expression and is frequently downregulated in MITF-low melanomas, it is not clear how SAMMSON expression would bemaintained in MITF-low invasive melanoma cells or cells in which SOX10 is downregulated due to BRAF inhibition (Sun et al., 2014).”
BackgroundSignaling and Immune Regulation in Melanoma Development and Responses to Therapy
Lin, W. M., & Fisher, D. E. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100208 · Cited by 52
Tissue-Agnostic Drug Development
Flaherty, K. T., Le, D. T., & Lemery, S. J. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_173855 · Cited by 52
Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
Chen, P.-Y., Muzumdar, M. D., Dorans, K. J., Robbins, R., Bhutkar, A., del Rosario, A., Mertins, P., Qiao, J., Schafer, A. C., Gertler, F., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2129 · Cited by 46
“Given that resistance against single-agent targeted therapies frequently emerges after prolonged treatment (19,20), it is critical to preemptively strategize treatment methods to circumvent resistance.”
Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma
Almeida, F. V., Douglass, S. M., Fane, M. E., & Weeraratna, A. T. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12736 · Cited by 44
“…Number: R01CA174746 and R01CA207935 K E Y W O R D S drug resistance, hypoxia, immunology, mechanotransduction, melanoma, oxidative stress factor 1 receptor (IGF1R), activated TGF pathway, hyperphosphor‐ ylated ERK, among others (Nazarian et al., 2010; Sun et al., 2014; Villanueva et al., 2010).”
BackgroundTolerant/Persister Cancer Cells and the Path to Resistance to Targeted Therapy
Swayden, M., Chhouri, H., Anouar, Y., & Grumolato, L. (2020) · Cells · doi:10.3390/cells9122601 · Cited by 52
ERBB1/2/3 Expression, Prognosis, and Immune Infiltration in Cutaneous Melanoma
Liu, S., Geng, R., Lin, E., Zhao, P., & Chen, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.602160 · Cited by 50
“Studies have shown that the TGF-β pathway can initiate EGFR expression (Sun et al., 2014), making EGFR fully pathogenic.”
BackgroundShi, X., Mihaylova, V. T., Kuruvilla, L., Chen, F., Viviano, S., Baldassarre, M., Sperandio, D., Martinez, R., Yue, P., Bates, J. G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608319113 · Cited by 50
“Similarly, knockdown of the transcription factor SOX10 in melanoma cell lines induces BRAF inhibitor resistance by induction of TβRII and TGF-β signaling, ultimately resulting in increased receptor tyrosine kinase expression (45).”
BackgroundTan, J., Liu, R., Zhu, G., Umbricht, C. B., & Xing, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004707117 · Cited by 47
“Although several molecular mechanisms for such drug resistance have been proposed (3, 4), little clinical progress has occurred in tackling it.”
BackgroundRTK Inhibitors in Melanoma: From Bench to Bedside
Sabbah, M., Najem, A., Krayem, M., Awada, A. H., Journé, F., & Ghanem, G. (2021) · Cancers · doi:10.3390/cancers13071685 · Cited by 48
“In addition, such activation has been also documented to cause secondary drug resistance in BRAF mutated patients under MAPK inhibitors thus opening the way to the use of EGFR inhibitors to overcome such resistance [20,110,111].”
BackgroundTumor Microenvironment as a Therapeutic Target in Melanoma Treatment
Kharouf, N., Flanagan, T. W., Hassan, S.-Y., Shalaby, H., Khabaz, M., Hassan, S.-L., Megahed, M., Haïkel, Y., Santourlidis, S., & Hassan, M. (2023) · Cancers · doi:10.3390/cancers15123147 · Cited by 54
“Although the successful targeting of these mutations improves overall survival of melanoma patients, acquired tumor resistance develops and increases continuously [163,164].”
BackgroundNishida, T., Doi, T., & Naito, Y. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.937707 · Cited by 46
“Third, when tumors have negative feedback on other survival signals downstream of target kinases, resistance after TKI therapy may be caused by feedback activation of alternative kinases as seen in BRAFmutated (V600E) melanomas [57-59].”
BackgroundSchmitt, A., Schmitz, W., Hufnagel, A., Schartl, M., & Meierjohann, S. (2015) · Biochemical Journal · doi:10.1042/bj20141204 · Cited by 45
Ungerleider, N., Han, C., Zhang, J., Yao, L., & Wu, T. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22592 · Cited by 45
Laurenzana, A., Margheri, F., Biagioni, A., Chillà, A., Pimpinelli, N., Ruzzolini, J., Peppicelli, S., Andreucci, E., Calorini, L., Serratì, S., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.024 · Cited by 45
“Given the notion that EGFR levels determine the response to BRAF inhibitor monotherapy [30] and taking in consideration the strong engagement between EGFR and uPAR in melanoma cells [31],we compared EGFR and uPAR protein levels in a panel of wild type and BRAF (V600E) mutant melanoma cell lines (Fig.”
BackgroundIlan, Y., & Spigelman, Z. S. (2020) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2020.100240 · Cited by 51
Béal, J., Pantolini, L., Noël, V., Barillot, E., & Calzone, L. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007900 · Cited by 53
“Some 55 subsequent studies have proposed context-based molecular explanations, often highlighting 56 surrounding genes or signalling pathways, such as a feedback activation of EGFR [21] or other 57 mechanisms [22,23].”
BackgroundDai, K., Huang, L., Chen, J., Yang, L., & Gong, Z. (2014) · Immunology · doi:10.1111/imm.12400 · Cited by 45
Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells
Huang, K., Yang, J., Ng, M. C., Ng, S., Welch, W. R., Muto, M. G., Berkowitz, R. S., & Ng, S. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.08.007 · Cited by 45
Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells
Hmada, Y. A., Brodell, R. T., Kharouf, N., Flanagan, T. W., AlAmodi, A. A., Hassan, S.-Y., Shalaby, H., Hassan, S.-L., Haïkel, Y., Megahed, M., et al. (2024) · Cancers · doi:10.3390/cancers16020470 · Cited by 48
“…epigenetic alterations to tumor cells and significant changes in their microenvironment [127,128], while the development of acquired/adaptive resistance results from tumor treatment-induced genetic and epigenetic alterations to key molecules of aberrant signaling pathways in tumor cells [129,130].”
BackgroundSMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer
Papadakis, A. I., Sun, C., Knijnenburg, T., Xue, Y., Grernrum, W., Hölzel, M., Nijkamp, W., Wessels, L. F. A., Beijersbergen, R. L., Bernards, R., et al. (2015) · Cell Research · doi:10.1038/cr.2015.16 · Cited by 46
“Additional details can be found at http://www.screeninc.nki.nl. shRNA “Dropout” Screen using a custom TRC Kinome Library was performed as described [32, 51].”
Self-citationde Almeida, L. N., Bagnerini, P., Fabrini, G., Hughes, B. D., & Lorenzi, T. (2019) · ESAIM Mathematical Modelling and Numerical Analysis · doi:10.1051/m2an/2019010 · Cited by 53
Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies
Diazzi, S., Tartare‐Deckert, S., & Deckert, M. (2020) · Cancers · doi:10.3390/cancers12061364 · Cited by 45
“In parallel, cell populations characterized by a dedifferentiated invasive signature, the upregulation of RTKs including platelet-derived growth factor receptor beta (PDGFRβ), epidermal growth factor Cancers 2020, 12, 1364 4 of 20 receptor (EGFR), nerve growth factor receptor (NGFR), insulin-like growth factor recepto…”
BackgroundInfluentialA systematic analysis of signaling reactivation and drug resistance
Kholodenko, B. Ν., Rauch, N., Kölch, W., & Rukhlenko, O. S. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109157 · Cited by 44
“2 Cell Reports 35, 109157, May 25, 2021 phosphatidylinositol 3-kinase (PI3K) inhibitors (Lito et al., 2012; Montero-Conde et al., 2013; Prahallad et al., 2012; Ryan et al., 2020; Sun et al., 2014; Yaeger and Corcoran, 2019).”
Ngiow, S. F., Meeth, K. M., Stannard, K. A., Barkauskas, D. S., Bollag, G. E., Bosenberg, M., & Smyth, M. J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1089381 · Cited by 46
SOX10-MITF pathway activity in melanoma cells
Tudrej, K. B., Czepielewska, E., & Kozłowska−Wojciechowska, M. (2016) · Archives of Medical Science · doi:10.5114/aoms.2016.60655 · Cited by 50
Oncogenic activity of SOX1 in glioblastoma
García, I., Aldaregia, J., Marjanović, J., Aldaz, P., Moreno‐Cugnon, L., Torres-Bayona, S., Carrasco‐García, E., Garros-Regulez, L., Egaña, L., Rubio, Á., et al. (2017) · Scientific Reports · doi:10.1038/srep46575 · Cited by 46
CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
Houles, T., Lavoie, G., Nourreddine, S., Cheung, W., Vaillancourt-Jean, É., Guérin, C. M., Bouttier, M., Grondin, B., Lin, S., Saba-El-Leil, M. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34179-8 · Cited by 40
ETS‐targeted therapy: can it substitute for MEK inhibitors?
Tetsu, O., & McCormick, F. P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0147-4 · Cited by 45
“This was recently identified as adaptive drug resistance, a subtype of primary (intrinsic or innate) drug resistance [36].”
BackgroundCoppé, J.-P., Mori, M., Pan, B., Yau, C., Wolf, D. M., Ruiz-Saenz, A., Brunen, D., Prahallad, A., Cornelissen-Steijger, P., Kemper, K., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0328-z · Cited by 36
Self-citationBernardo, M., Tolstykh, T., Zhang, Y., Bangari, D. S., Cao, H., Heyl, K. A., Lee, J. S., Malkova, N. V., Malley, K., Márquez, E. J., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1881268 · Cited by 46
Maverakis, E., Tran, K. A., Cheng, M., Mitra, A., Ogawa, H., Shi, V. Y., Olney, L. P., & Kloxin, A. M. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s93545 · Cited by 51
“Indeed, patient-derived samples revealed tumor-associated upregulation of PDGFR3(16,74) in vemurafenib-resistant cells, which was shown to be SOX10 and TGFBR2 dependent.(74) MEK inhibition is ineffective in these resistant strains, demonstrating that MEK/MAPK is not the key downstream pathway here.”
BackgroundThe role of phenotypic plasticity in the escape of cancer cells from targeted therapy
Emmons, M. F., Faião‐Flores, F., & Smalley, K. S. M. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.06.014 · Cited by 42
“Although it has been rarely stated, there is good evidence that the phenotypic state characterized by MITF overlaps significantly with the EMT-like state regulated through TGF-β.”
BackgroundInfluential
Metadata
- Authors
- Sun, C., Wang, L., Huang, S., Heynen, G. J. J. E., Prahallad, A., Robert, C., Haanen, J., Blank, C., Wesseling, J., Willems, S. M., Zecchin, D., Hobor, S., Bajpe, P. K., Lieftink, C., Mateus, C., Vagner, S., Grernrum, W., Hofland, I., Schlicker, A., Wessels, L. F. A., Beijersbergen, R. L., Bardelli, A., Di Nicolantonio, F., Eggermont, A. M. M., & Bernards, R.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Institut Gustave Roussy (FR)
- Candiolo Cancer Institute (IT)
- IFOM (IT)
- ORCID
- Sun, Chong
- Wang, Liqin
- Huang, Sidong
- Heynen, Guus J. J. E.
- Prahallad, Anirudh
- Robert, Caroline
- Haanen, John
- Blank, Christian
- Wesseling, Jelle
- Willems, Stefan M.
- Zecchin, Davide
- Lieftink, Cor
- Hofland, Ingrid
- Schlicker, Andreas
- Wessels, Lodewyk F. A.
- Beijersbergen, Roderick L.
- Bardelli, Alberto
- Eggermont, Alexander M. M.
- Venue
- Nature
- Published
- 2014-03-26
- Volume
- 508
- Issue
- 7494
- Pages
- 118-122
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985928174
- Cited by
- 888
- References
- 30
- Citations by year
- 2026: 29 · 2025: 43 · 2024: 62 · 2023: 58 · 2022: 90 · 2021: 81 · 2020: 71 · 2019: 76 · 2018: 75 · 2017: 83 · 2016: 71 · 2015: 107 · 2014: 39
- FWCI
- 40.97
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RePEc: Research Papers in Economics (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (MOP130540)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- BRAF inhibitor resistance, SOX10, TGF-beta signaling, PDGFRβ, oncogene-induced senescence, drug holidays, MEK inhibitors, adaptive resistance, shRNA screen, cell proliferation, tumor heterogeneity, drug re-sensitization, receptor tyrosine kinase
- MeSH terms
- Vemurafenib, Animals, Antineoplastic Agents, Female, Flow Cytometry, Humans, Indoles, Melanoma, Sulfonamides, Signal Transduction, Gene Library, Gene Expression Regulation, Neoplastic, Transforming Growth Factor beta, Cellular Senescence, Drug Resistance, Neoplasm, Receptor Protein-Tyrosine Kinases, Receptor, Platelet-Derived Growth Factor beta, Mitogen-Activated Protein Kinase Kinases, RNA, Small Interfering, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Cell Proliferation, Mice, SOXE Transcription Factors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.